# Val J Lowe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5082494/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 265 papers | 14,456 citations | 20797 60 h-index | 29127 104 g-index |
| 268 all docs | 268 docs citations | 268 times ranked | 13530 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216. | 0.4 | 581 |
| 2 | An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58. | 2.4 | 388 |
| 3 | Plasma phosphoâ€tau181 increases with Alzheimer's disease clinical severity and is associated with tauâ€• and amyloidâ€positron emission tomography. Alzheimer's and Dementia, 2018, 14, 989-997. | 0.4 | 386 |
| 4 | Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557. | 3.3 | 348 |
| 5 | Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528. | 3.7 | 309 |
| 6 | Age, Sex, andAPOEÎµ4 Effects on Memory, Brain Structure, and Î²-Amyloid Across the Adult Life Span. JAMA Neurology, 2015, 72, 511. | 4.5 | 305 |
| 7 | Age-specific population frequencies of cerebral Î²-amyloidosis and neurodegeneration among people with normal cognitive function aged 50â€“89 years: a cross-sectional study. Lancet Neurology, The, 2014, 13, 997-1005. | 4.9 | 297 |
| 8 | Clinicopathologic and<sup>11</sup>C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381. | 3.7 | 270 |
| 9 | Age-specific and sex-specific prevalence of cerebral Î²-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50â€“95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444. | 4.9 | 241 |
| 10 | Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933. | 1.4 | 240 |
| 11 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316. | 3.8 | 223 |
| 12 | Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771. | 3.7 | 222 |
| 13 | Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287. | 3.7 | 218 |
| 14 | Comparison of <sup>18</sup>F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886. | 2.8 | 183 |
| 15 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174. | 4.5 | 182 |
| 16 | Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759. | 3.7 | 170 |
| 17 | Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer. Molecular Imaging and Biology, 2005, 7, 422-430. | 1.3 | 163 |
| 18 | Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e161. | 3.1 | 163 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw154. | 1.7 | 163 |
| 20 | Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105. | 1.5 | 162 |
| 21 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159. | 1.1 | 162 |
| 22 | Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. JAMA Neurology, 2016, 73, 85. | 4.5 | 160 |
| 23 | Multisite study of the relationships between antemortem [<sup>11</sup>C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216. | 0.4 | 155 |
| 24 | AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67. | 2.8 | 152 |
| 25 | Association of Excessive Daytime Sleepiness With Longitudinal Î²-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672. | 4.5 | 150 |
| 26 | Dementia with Lewy bodies. Neurology, 2014, 83, 801-809. | 1.5 | 143 |
| 27 | Prostate cancerâ€“specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology, 2018, 8, 28-39. | 1.1 | 140 |
| 28 | Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718. | 2.8 | 136 |
| 29 | [<sup>18</sup>F]AVâ€1451 tau positron emission tomography in progressive supranuclear palsy. Movement Disorders, 2017, 32, 124-133. | 2.2 | 136 |
| 30 | The evolution of primary progressive apraxia of speech. Brain, 2014, 137, 2783-2795. | 3.7 | 134 |
| 31 | Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236. | 1.1 | 133 |
| 32 | The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242. | 3.7 | 129 |
| 33 | White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491. | 3.7 | 126 |
| 34 | Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715. | 3.9 | 125 |
| 35 | [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 931-933. | 3.9 | 116 |
| 36 | Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurology, 2018, 75, 970. | 4.5 | 116 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's and Dementia, 2021, 17, 1554-1574. | 0.4 | 114 |
| 38 | Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108. | 4.5 | 114 |
| 39 | Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405. | 15.2 | 114 |
| 40 | Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571. | 0.4 | 113 |
| 41 | 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106. | 1.5 | 108 |
| 42 | Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718. | 4.5 | 107 |
| 43 | Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65. | 0.8 | 106 |
| 44 | Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64. | 4.9 | 104 |
| 45 | Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556. | 1.2 | 94 |
| 46 | Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by <sup>11</sup> C-Choline Positron Emission Tomography/Computerized Tomography. Journal of Urology, 2015, 193, 111-116. | 0.2 | 92 |
| 47 | <sup>18</sup>F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638. | 2.8 | 91 |
| 48 | Tauâ€PET uptake: Regional variation in average SUVR and impact of amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 21-30. | 1.2 | 86 |
| 49 | Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068. | 1.5 | 81 |
| 50 | Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014. | 0.4 | 80 |
| 51 | Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. Neurobiology of Disease, 2019, 121, 327-337. | 2.1 | 79 |
| 52 | Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150. | 3.7 | 74 |
| 53 | Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967. | 1.5 | 73 |
| 54 | [<sup>18</sup>F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611. | 2.8 | 73 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147. | 3.7 | 72 |
| 56 | Effect of intellectual enrichment on AD biomarker trajectories. Neurology, 2016, 86, 1128-1135. | 1.5 | 71 |
| 57 | Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95. | 4.5 | 69 |
| 58 | Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750. | 3.7 | 68 |
| 59 | Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160. | 3.7 | 68 |
| 60 | Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287. | 3.7 | 68 |
| 61 | [<sup>18</sup>F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257. | 2.8 | 67 |
| 62 | FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217. | 3.7 | 67 |
| 63 | Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291. | 1.5 | 65 |
| 64 | 18F-FDG PET of patients with HÃ¼rthle cell carcinoma. Journal of Nuclear Medicine, 2003, 44, 1402-6. | 2.8 | 64 |
| 65 | Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433. | 2.1 | 63 |
| 66 | The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer, 2001, 92, 2341-2348. | 2.0 | 62 |
| 67 | Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39. | 1.5 | 62 |
| 68 | Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268. | 1.5 | 62 |
| 69 | In vivo <sup>18</sup> F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954. | 1.5 | 60 |
| 70 | Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. NeuroImage, 2017, 144, 113-127. | 2.1 | 59 |
| 71 | Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials, 2014, 35, 1967-1976. | 5.7 | 58 |
| 72 | Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. Journal of Controlled Release, 2014, 185, 121-129. | 4.8 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398. | 0.4 | 58 |
| 74 | White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547. | 4.5 | 57 |
| 75 | Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412. | 1.5 | 57 |
| 76 | Abnormal Fluorodeoxyglucose PET in Pulmonary Langerhans Cell Histiocytosis. Chest, 2009, 135, 1542-1549. | 0.4 | 55 |
| 77 | Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823. | 1.4 | 54 |
| 78 | Cortical Î²-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. Translational Psychiatry, 2019, 9, 123. | 2.4 | 54 |
| 79 | Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631. | 1.9 | 53 |
| 80 | Cerebral microbleeds. Neurology, 2019, 92, e253-e262. | 1.5 | 53 |
| 81 | Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251. | 0.6 | 52 |
| 82 | Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424. | 5.3 | 52 |
| 83 | Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348. | 0.9 | 51 |
| 84 | Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294. | 3.7 | 51 |
| 85 | Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain and Language, 2015, 142, 45-53. | 0.8 | 49 |
| 86 | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716. | 2.8 | 49 |
| 87 | Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939. | 0.4 | 48 |
| 88 | A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. Journal of Alzheimer's Disease, 2019, 67, 181-195. | 1.2 | 48 |
| 89 | Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clinical Neuropsychologist, 2017, 31, 99-117. | 1.5 | 47 |
| 90 | Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology, 2013, 80, 2130-2137. | 1.5 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152. | 1.4 | 46 |
| 92 | Influence of amyloid and APOE on cognitive performance in a late middleâ€aged cohort. Alzheimer's and Dementia, 2016, 12, 281-291. | 0.4 | 45 |
| 93 | Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. Journal of Urology, 2017, 197, 129-134. | 0.2 | 45 |
| 94 | Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724. | 1.2 | 45 |
| 95 | Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706. | 1.6 | 44 |
| 96 | Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex, 2018, 99, 358-374. | 1.1 | 42 |
| 97 | Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. Brain, 2018, 141, 302-317. | 3.7 | 42 |
| 98 | Increased Brain Glucose Uptake After 12 Weeks of Aerobic High-Intensity Interval Training in Young and Older Adults. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 221-227. | 1.8 | 41 |
| 99 | Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909. | 2.8 | 41 |
| 100 | <sup>11</sup>C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. Radiographics, 2016, 36, 279-292. | 1.4 | 40 |
| 101 | Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214. | 1.0 | 40 |
| 102 | Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877. | 2.8 | 40 |
| 103 | White Matter Reference Region in PET Studies of <sup>11</sup>C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589. | 2.8 | 37 |
| 104 | APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375. | 5.8 | 37 |
| 105 | The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685. | 0.4 | 36 |
| 106 | White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017. | 1.5 | 35 |
| 107 | FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616. | 1.2 | 35 |
| 108 | Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535. | 0.4 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749. | 1.4 | 34 |
| 110 | A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452. | 5.8 | 34 |
| 111 | Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Postâ€“radical Prostatectomy. European Urology Focus, 2016, 2, 522-531. | 1.6 | 33 |
| 112 | 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. NeuroImage: Clinical, 2018, 18, 897-902. | 1.4 | 33 |
| 113 | Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482. | 3.7 | 33 |
| 114 | MRI Outperforms [18F]AVâ€‘1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113. | 2.2 | 33 |
| 115 | The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism and Related Disorders, 2014, 20, 180-185. | 1.1 | 32 |
| 116 | MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304. | 0.4 | 32 |
| 117 | Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160. | 2.8 | 32 |
| 118 | Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022. | 2.8 | 32 |
| 119 | Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199. | 3.0 | 32 |
| 120 | APOE Îµ4 influences Î²â€‘amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimer's and Dementia, 2014, 10, 630-636. | 0.4 | 31 |
| 121 | BBBomics-Human Blood Brain Barrier Transcriptomics Hub. Frontiers in Neuroscience, 2016, 10, 71. | 1.4 | 31 |
| 122 | Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947. | 1.4 | 31 |
| 123 | Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199. | 1.5 | 31 |
| 124 | <scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156. | 2.8 | 31 |
| 125 | Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1383-1395. | 0.4 | 31 |
| 126 | Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain. PLoS ONE, 2014, 9, e97655. | 1.1 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Comparison of [ 18 F]Flutemetamol and [ 11 C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. NeuroImage: Clinical, 2017, 16, 295-302. | 1.4 | 30 |
| 128 | A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161. | 1.2 | 29 |
| 129 | Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676. | 0.8 | 29 |
| 130 | Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From 18F-DOPA-PET Imaging. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1339-1346. | 0.4 | 29 |
| 131 | Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802. | 1.5 | 28 |
| 132 | Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643. | 1.2 | 27 |
| 133 | Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology, 2016, 86, 2077-2084. | 1.5 | 27 |
| 134 | Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131. | 1.5 | 27 |
| 135 | Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 48, 3-9. | 1.1 | 27 |
| 136 | Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34. | 1.5 | 27 |
| 137 | Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217. | 4.5 | 27 |
| 138 | FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754. | 1.4 | 27 |
| 139 | Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789. | 0.4 | 26 |
| 140 | Contributions of imprecision in <scp>PET</scp>â€<scp>MRI</scp> rigid registration to imprecision in amyloid <scp>PET</scp><scp>SUVR</scp> measurements. Human Brain Mapping, 2017, 38, 3323-3336. | 1.9 | 26 |
| 141 | Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. Journal of Neuro-Oncology, 2018, 137, 583-591. | 1.4 | 26 |
| 142 | The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging. Frontiers in Neuroscience, 2018, 12, 238. | 1.4 | 26 |
| 143 | <sup>18</sup>Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352. | 2.2 | 26 |
| 144 | Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC). Breast Cancer, 2021, 28, 1073-1086. | 1.3 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225. | 3.7 | 26 |
| 146 | Preparation and Preliminary Evaluation of <sup>63</sup>Zn-Zinc Citrate as a Novel PET Imaging Biomarker for Zinc. Journal of Nuclear Medicine, 2014, 55, 1348-1354. | 2.8 | 25 |
| 147 | Clinical significance of incidental [18ÂF]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study. BMC Gastroenterology, 2016, 16, 125. | 0.8 | 25 |
| 148 | Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. EJNMMI Research, 2017, 7, 90. | 1.1 | 25 |
| 149 | Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355. | 1.7 | 25 |
| 150 | Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. American Journal of Geriatric Psychiatry, 2021, 29, 179-191. | 0.6 | 25 |
| 151 | Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029. | 1.2 | 24 |
| 152 | Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946. | 1.5 | 24 |
| 153 | Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259. | 2.1 | 24 |
| 154 | Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475. | 4.5 | 23 |
| 155 | Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399. | 1.0 | 23 |
| 156 | Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352. | 1.2 | 23 |
| 157 | 18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€"A Multicenter Retrospective Study. Cancers, 2019, 11, 700. | 1.7 | 23 |
| 158 | Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE Îµ4 allele. Alzheimer's and Dementia, 2020, 16, 598-609. | 0.4 | 23 |
| 159 | First PET Imaging Studies With <sup>63</sup>Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. Molecular Imaging, 2016, 15, 153601211667379. | 0.7 | 22 |
| 160 | Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698. | 1.5 | 22 |
| 161 | Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. Journal of Alzheimer's Disease, 2018, 64, 281-290. | 1.2 | 22 |
| 162 | Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439. | 2.8 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108. | 1.5 | 21 |
| 164 | Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533. | 2.8 | 21 |
| 165 | Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CTâ€"Identified Oligometastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6376-6383. | 3.2 | 21 |
| 166 | Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42. | 1.5 | 20 |
| 167 | The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Parkinsonism and Related Disorders, 2020, 81, 34-40. | 1.1 | 20 |
| 168 | Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117. | 1.2 | 19 |
| 169 | Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216. | 1.2 | 19 |
| 170 | Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61. | 1.1 | 19 |
| 171 | Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246. | 1.5 | 19 |
| 172 | <sup>1</sup> H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399. | 1.5 | 18 |
| 173 | Confirmation of <sup>123</sup>I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635. | 2.8 | 18 |
| 174 | Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. Neurology, 2020, 94, e1571-e1579. | 1.5 | 18 |
| 175 | Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48. | 2.4 | 18 |
| 176 | Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261. | 1.5 | 18 |
| 177 | Assessment of Lymphoma Therapy Using (18)F-FDG PET. Journal of Nuclear Medicine, 2002, 43, 1028-30. | 2.8 | 18 |
| 178 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109. | 0.5 | 17 |
| 179 | 18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040. | 1.5 | 17 |
| 180 | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567. | 2.8 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721. | 1.7 | 17 |
| 182 | Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506. | 0.4 | 17 |
| 183 | TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85. | 0.9 | 16 |
| 184 | The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 877-883. | 1.7 | 16 |
| 185 | Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048. | 1.5 | 15 |
| 186 | Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440. | 2.1 | 15 |
| 187 | Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013. | 1.5 | 15 |
| 188 | Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66. | 0.4 | 14 |
| 189 | Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602. | 1.5 | 14 |
| 190 | White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16. | 2.4 | 14 |
| 191 | A longitudinal investigation of AÎ², anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831. | 0.4 | 14 |
| 192 | Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using <sup>11</sup> C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. Journal of Urology, 2018, 199, 726-733. | 0.2 | 13 |
| 193 | Î²-Amyloid PET and <sup>123</sup> I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, . | 1.5 | 13 |
| 194 | White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076. | 1.5 | 13 |
| 195 | Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202. | 1.5 | 13 |
| 196 | Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850. | 1.4 | 13 |
| 197 | Perceived Misinterpretation Rates in Oncologic <sup>18</sup>F-FDG PET/CT Studies: A Survey of Referring Physicians. Journal of Nuclear Medicine, 2014, 55, 1925-1929. | 2.8 | 12 |
| 198 | NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. Neurology: Clinical Practice, 2014, 4, 470-473. | 0.8 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159. | 1.5 | 12 |
| 200 | Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology, 2020, 20, 1115-1122. | 0.5 | 12 |
| 201 | Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. Journal of Neurology, 2020, 267, 2603-2611. | 1.8 | 12 |
| 202 | Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182. | 1.5 | 12 |
| 203 | Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017. | 1.5 | 12 |
| 204 | Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, . | 1.5 | 12 |
| 205 | The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18. | 1.5 | 11 |
| 206 | Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98. | 1.5 | 11 |
| 207 | Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238. | 1.5 | 11 |
| 208 | Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264. | 2.2 | 11 |
| 209 | Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. NeuroImage: Clinical, 2016, 11, 90-98. | 1.4 | 10 |
| 210 | Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2018, 66, 2274-2281. | 1.3 | 10 |
| 211 | The influence of Î²-amyloid on [ <sup>18</sup> F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722. | 1.5 | 10 |
| 212 | High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-Î²Distribution between Brain and Plasma. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 308-316. | 1.3 | 10 |
| 213 | Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808. | 1.5 | 10 |
| 214 | Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378. | 1.4 | 9 |
| 215 | Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421. | 1.6 | 9 |
| 216 | Association of Cortical and Subcortical Î²-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 64-71. | 0.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355. | 1.0 | 9 |
| 218 | Brain Metabolic Changes with Longitudinal Transcutaneous Afferent Patterned Stimulation in Essential Tremor Subjects. Tremor and Other Hyperkinetic Movements, 2020, 10, 52. | 1.1 | 9 |
| 219 | The A20/TNFAIP3-CDC20-CASP1 Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer. Anticancer Research, 2022, 42, 681-695. | 0.5 | 9 |
| 220 | 1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26. | 1.5 | 9 |
| 221 | ExÂVivo Cell Therapy by Ectopic Hepatocyte Transplantation Treats the Porcine Tyrosinemia Model of Acute Liver Failure. Molecular Therapy - Methods and Clinical Development, 2020, 18, 738-750. | 1.8 | 8 |
| 222 | <sup>11</sup>C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen â‰¥0.1 ng/ml. Journal of Cancer Research and Therapeutics, 2021, 17, 358. | 0.3 | 8 |
| 223 | Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. Journal of Alzheimer's Disease, 2022, 86, 491-498. | 1.2 | 8 |
| 224 | Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743. | 1.2 | 7 |
| 225 | Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389. | 1.2 | 7 |
| 226 | Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36. | 1.5 | 7 |
| 227 | Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128. | 1.8 | 7 |
| 228 | Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143. | 1.7 | 7 |
| 229 | Esophageal cancer and head and neck cancer. Seminars in Roentgenology, 2002, 37, 140-150. | 0.2 | 6 |
| 230 | Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263. | 0.2 | 6 |
| 231 | FDGâ€PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDGâ€PET/CT cN0. Otolaryngology - Head and Neck Surgery, 2021, 164, 1230-1239. | 1.1 | 6 |
| 232 | Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. Clinical Genitourinary Cancer, 2021, 19, 223-229. | 0.9 | 6 |
| 233 | Design, Synthesis, and Preliminary Evaluation of [<sup>68</sup>Ga]Ga-NOTA-Insulin as a PET Probe in an Alzheimerâ€™s Disease Mouse Model. Bioconjugate Chemistry, 2022, 33, 892-906. | 1.8 | 6 |
| 234 | Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas. Physics and Imaging in Radiation Oncology, 2018, 6, 94-100. | 1.2 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43. | 1.1 | 5 |
| 236 | Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 17-28. | 0.7 | 5 |
| 237 | Neurodegeneration of the visual word form area in a patient with word form alexia. Neurology and Clinical Neuroscience, 2021, 9, 359-360. | 0.2 | 5 |
| 238 | PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 137-137. | 0.6 | 5 |
| 239 | Natural COA water inhibits mitochondrial ROS-mediated apoptosis through Plk3 downregulation under STZ diabetic stress in pancreatic Î²-cell lines. Biochemistry and Biophysics Reports, 2022, 30, 101247. | 0.7 | 5 |
| 240 | Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290. | 0.9 | 4 |
| 241 | Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254. | 0.3 | 4 |
| 242 | Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation. Neurocase, 2020, 26, 211-219. | 0.2 | 4 |
| 243 | Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. Neurocase, 2021, 27, 212-222. | 0.2 | 4 |
| 244 | Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. Journal of Alzheimer's Disease, 2021, 80, 397-405. | 1.2 | 4 |
| 245 | Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€“Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534. | 1.5 | 4 |
| 246 | Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675. | 2.2 | 4 |
| 247 | In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.0000000000000755. | 0.8 | 4 |
| 248 | Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. Molecular Pharmaceutics, 2021, 18, 4148-4161. | 2.3 | 4 |
| 249 | Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547. | 1.2 | 4 |
| 250 | CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200. | 1.5 | 4 |
| 251 | An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268. | 1.0 | 3 |
| 252 | Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140. | 1.5 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Brain amyloid, cortical thickness, and changes in activities of daily living. Annals of Clinical and Translational Neurology, 2020, 7, 474-485. | 1.7 | 3 |
| 254 | Prognostic role of 11Câ€choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate, 2022, 82, 41-48. | 1.2 | 3 |
| 255 | Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583. | 3.9 | 3 |
| 256 | Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201. | 0.9 | 2 |
| 257 | Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Advances in Radiation Oncology, 2019, 4, 79-89. | 0.6 | 2 |
| 258 | Radiation induced oxidation of [18F]fluorothia fatty acids under cGMP manufacturing conditions. Nuclear Medicine and Biology, 2020, 80-81, 13-23. | 0.3 | 2 |
| 259 | Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625. | 1.2 | 2 |
| 260 | Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451. | 0.7 | 1 |
| 261 | Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual. Journal of Alzheimer's Disease, 2021, , 1-6. | 1.2 | 1 |
| 262 | 3D registration of micro PET-CT for measurable correlates of dyspeptic symptoms in mice. Proceedings of SPIE, 2009, 7262, 72620Z. | 0.8 | 0 |
| 263 | Reply from Authors re: Alberto Bossi, Nicolas Mottet, Pierre Blanchard. Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? Eur Urol 2017;71:349â€“50. European Urology, 2017, 71, 351-352. | 0.9 | 0 |
| 264 | Your brain scan may be a reflection of your genes. Brain, 2018, 141, 2539-2541. | 3.7 | 0 |
| 265 | Prior Menopausal Hormone Treatments And Association of Peripheral Markers of Neurovascular Unit Integrity And Î²â€amyloid in The Brains of Menopausal Women. FASEB Journal, 2018, 32, lb449. | 0.2 | 0 |